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Background: There is very little evidence regarding head to head comparisons of 
psychosocial interventions and pharmacological interventions for psychosis. We 
aimed to determine whether it is feasible to conduct a randomised controlled trial 
comparing Cognitive Behaviour Therapy (CBT) with antipsychotic medication and a 
combination of both in people with psychosis. 
Methods: A single-site, single-blind pilot randomised controlled trial comparing CBT 
with antipsychotics with the combination recruited 75 participants with psychosis 
(aged 16-43 years; mean 23.61; SD 6.06), largely from early intervention services in 
NHS Trusts across Greater Manchester. 26 were assigned to CBT, 24 to 
antipsychotics and 25 to the combination. Participants were followed-up over 12 
months. CBT incorporated up to 26 sessions over 6 months (mean sessions 14.39) 
plus up to four booster sessions. Choice and dose of antipsychotics were at the 
discretion of the treating consultant (median duration of total antipsychotic treatment 
was 44.5 weeks, SD 16.1, range 2-52). The primary outcome was feasibility data 
(recruitment, retention, acceptability) and the main effectiveness outcome was the 
Positive and Negative Syndrome Scale (PANSS) total score, which provides a 
continuous measure of psychiatric symptoms associated with psychotic disorders on 
the basis of a structured psychiatric interview (assessed at baseline, 6, 12, 24 and 
52 weeks). The study was prospectively registered as International Standard 
Randomised Controlled Trial number ISRCTN06022197. 
Outcomes: The trial recruited to target with a low referral:randomisation rate 
(138:75), had low rates of attrition (<20%), high rates of retention (>80%) and low 
rates of participants receiving interventions they were not allocated to (12%). The 
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majority of participants (73/75) were experiencing first episode psychosis (FEP) and 
recruited from Early Intervention Teams. The majority of participants allocated to 
CBT (n=40 out of 51, 78%) attended 6 or more sessions, with only one participant 
(2%) attending no sessions, and 404 of 557 homework tasks were completed (73%). 
Of the 49 participants randomised to antipsychotics, 11 (22%) were not prescribed a 
regular antipsychotic; the median duration of total antipsychotic treatment was 44.5 
weeks (SD 16.1, range 2-52) and mean self-rated adherence was 77% (range 0 -
100%, SD 29.19). Changes in effectiveness outcomes were analysed following the 
intention-to-treat principle, using random effects models, adjusted for age, gender 
and baseline symptoms. Safety outcomes were analysed on an as treated basis. 
Psychiatric symptoms, measured by PANSS Total, were significantly reduced over 
time across all conditions. The combined intervention was more effective than CBT 
monotherapy, but not antipsychotic monotherapy (PANSS Total: comparison of 
combined to antipsychotics = -4.52; SD = 2.44; 95% CI -9.30 to 0.26; p = 0.064; 
comparison of combined to CBT = -5.65; SD = 2.41; 95% CI -10.37 to -0.93; p = 
0.019). There was no difference between the monotherapies (PANSS Total: 
comparison of CBT with antipsychotics = -1.13; SD = 2.39; 95% CI -5.81 to 3.55; p = 
0.637). CBT monotherapy had less side effects than the two treatments that included  
antipsychotics (ANNSERS number of side effects: comparison of CBT with 
antipsychotics = 3.22; SD = 1.35; 95% CI 0.58 to 5.87; p = 0.017; comparison of 
CBT with combined = 3.99; SD = 1.35; 95% CI 1.36 to 6.64; p = 0.003). Only one 
Serious Adverse Event was considered related to the trial (an overdose of 3 
paracetamol in the CBT as treated group).  
Interpretation: This is the first trial to show it is feasible and safe to conduct a head-
to-head clinical trial comparing CBT with antipsychotics and the combination in 
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people with FEP. An adequately powered efficacy and effectiveness  trial is required 
to provide robust evidence.  
Funding: This article outlines independent research funded by the National Institute 
for Health Research (NIHR) under its Research for Patient Benefit (RfPB) 
Programme (Grant Reference Number PB-PG- 1112-29057). 
Key words: Schizophrenia; Cognitive therapy; Psychosis; antipsychotic medication 
 
 
Declaration of interest: APM, PF and SB deliver training workshops and have written 
textbooks on the topic of CBT for psychosis, for which they receive fees. All authors 
have conducted funded research on CBT for psychosis and LD, RE, PMH, ARY 
have conducted funded research on antipsychotics. APM, PF, SEB, EKM, AS, NH, 
JPC and VB deliver CBT in the NHS. DS is an expert adviser for the National 
Institute of Health and Care Excellence (NICE) Centre for Guidelines and a board 
member of the National Collaborating Centre of Mental Health (NCCMH); these are 
my personal views and not those of NICE or NCCMH. PMH has received honoraria 
for lecturing and/or consultancy work from Allergan, Galen, Janssen, Lundbeck, 
NewBridge Pharmaceuticals, Otsuka, Sunovion and Teva plus conference support 
from Janssen, Lundbeck and Sunovion. ARY has received honoraria from Janssen 




Research in Context: 
Evidence before this study: We searched PubMed up to January 30, 2018, with the 
terms “schizophrenia”, “psychosis”, “psychological therapy”, “psychosocial 
intervention”, “CBT”, “antipsychotic” and “neuroleptic”. We did not apply any 
language restrictions. Although several systematic reviews and meta-analyses have 
found that there is robust evidence that antipsychotics are superior to placebo (1, 2) 
and that CBT for psychosis in addition to antipsychotics is superior to treatment as 
usual (3), there are no randomised controlled trials that provide head to head 
evidence comparing CBT and antipsychotics. A recent Cochrane review concluded 
that there was no usable data to answer the question of relative efficacy of 
antipsychotic medication and psychosocial interventions in early episode psychosis 
(4) .  
Added value of this study: It is possible to conduct a methodologically rigorous 
clinical trial that randomises participants with psychosis to psychological treatment, 
pharmacological treatment or the combination. Our study suggests that antipsychotic 
medication, CBT and the combined intervention are acceptable, safe and helpful 
treatments for people with early psychosis, but provides some indications that the 
treatments may have different cost-benefit profiles.  
Implications of all the available evidence: An adequately powered efficacy and 
effectiveness trial is now required. Such a trial could test hypotheses regarding 
superiority (e.g. combined treatment being superiority to monotherapies for 
effectiveness) and non-inferiority (e.g. between monotherapies). Our preliminary 
findings appear consistent with current guidelines (e.g. CG178) that recommend 
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informed choices and shared decision making regarding treatment options for early 







Schizophrenia and psychosis are associated with significant personal, social and 
economic  costs. There is high quality evidence from clinical trials that both 
antipsychotic medication and Cognitive Behaviour Therapy (CBT) can be helpful to 
adults with a diagnosis of schizophrenia and other psychoses. Many clinical 
guidelines, therefore, suggest that people with psychosis should be offered both 
antipsychotic medication and CBT (as well as family intervention) and should be 
involved in collaborative decisions regarding the treatment options they choose (5). 
However, neither antipsychotics nor CBT are effective for everyone and the 
individual cost-benefit ratios of such treatments will vary considerably, both between 
and within individuals.  
The cost-benefit ratio of such treatments is a balance between efficacy and adverse 
effects (or wanted and unwanted effects). Recent meta-analyses of Randomised 
Controlled Trials (RCTs) of CBT, added to antipsychotics, for psychosis (3, 6, 7) 
have found effect sizes for both total symptoms and positive symptoms in the small 
to moderate range (generally 0.3-0.4 relative to treatment as usual, although this 
reduces when lower quality trials are excluded). Recent meta-analyses of 
antipsychotic medication relative to placebo also show modest benefits on total and 
positive symptoms (1, 8), with the most comprehensive meta-analysis in chronic 
schizophrenia reporting a standardised effect size for total symptoms of 0.47 (9). 
However, while CBT and antipsychotics demonstrate superiority over comparators 
(treatment as usual and placebo respectively) to a statistically significant level, the 
proportion of individuals who achieve a clinically meaningful benefit is modest. The 
figure will depend largely on subject characteristics and how one defines clinical 
improvement.  For example, a recent meta-analysis (9) showed that 51% of multi-
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episode patients had at least a minimal response (≥20% reduction in PANSS/BPRS) 
reducing to 23% when the more stringent criterion of a good response was applied 
(≥50% reduction PANSS/BPRS).  Comparative rates with antipsychotic treatment in 
first episode psychosis were 81% for a minimal response and 52% for a good 
response (10). It has also been claimed that conclusions regarding the efficacy of 
CBT are exaggerated, since most large, well-conducted trials have failed to 
demonstrate a significant effect at end of treatment and the effect sizes are reduced 
overall if meta-analyses are limited to studies of high quality (3). 
Antipsychotics are associated with a wide range of adverse effects though the risks 
vary significantly between individual drugs (1). Side effects can impair quality of life, 
cause stigma, reduce adherence with medication and cause physical morbidity and 
mortality (11). Metabolic effects (weight gain and elevation of blood lipids and 
glucose) are a particular concern given the increased cardiovascular mortality seen 
in people with psychosis (12). Other adverse effects include sedation, sexual 
dysfunction, extrapyramidal symptoms, hyperprolactinemia, anticholinergic effects, 
cardiac arrhythmias and sudden cardiac death (11).  
Adverse effects for CBT for psychosis have not been well studied (3) and it is clear 
that research trials of psychological therapies need to improve their measurement of 
adverse effects. However, side effects that have been suggested to be likely, such 
as stigma and deterioration of mental state (13), have not been found when they 
have been measured in clinical trials of CBT for people with psychotic experiences; 
in fact, CBT can result in significant reductions of these factors (14, 15). However, 
there is some evidence that CBT delivered in the context of a poor therapeutic 
relationship may be harmful (16). 
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While most evidence for efficacy of CBT for psychosis is from randomised controlled 
trials where CBT is provided as an adjunct to antipsychotic medication (i.e. a 
combination of both is compared to antipsychotics alone), there is some preliminary 
evidence to suggest that CBT may be helpful for people with psychosis who are not 
taking antipsychotic medication. A recent RCT (n=74) established the safety and 
acceptability of using CBT as an alternative to antipsychotics in people who had 
chosen not to take them (15). This trial also found that participants allocated to CBT 
improved significantly on overall psychiatric symptoms (PANSS total), dimensions of 
psychotic symptoms and social functioning over 18 months.. There is currently no 
evidence regarding the relative head-to-head efficacy or acceptability of CBT and 
antipsychotics in schizophrenia. Indeed, a Cochrane review identified only 5 
controlled trials in early episode schizophrenia comparing antipsychotic medication 
to either placebo (3 trials) or a psychosocial intervention of any sort (one trial of 
individual psychotherapy and one of milieu therapy) (4). The authors concluded it 
was not possible to reach any definitive conclusions about relative efficacy.    
The COMPARE trial (ISRCTN06022197) is a single-site, three-arm pilot and 
feasibility RCT comparing CBT with antipsychotics with a combined treatment in 
people with psychosis. The primary aim is to assess the feasibility of such a trial, 
including analysis of recruitment rates (including willingness to be randomised), 
quality of data collection and follow–up (attrition), and the safety and acceptability of 
the interventions (in particular, the CBT monotherapy). Secondary aims include a 
preliminary examination of the effects on clinical, personal and social outcomes and 




Study design and participants  
The study was a single-blind, randomised, controlled pragmatic pilot and feasibility 
trial that was conducted between April 2014 and June 2017 in Manchester, UK. It 
was prospectively registered in March 2014 (ISRCTN06022197). The recruitment 
target was set at 75 (see previously published protocol paper for sample size 
justification (17)), and this was achieved between May 2014 and August 2016. 
Inclusion criteria required that participants either met International Classification of 
Diseases–tenth revision (ICD-10) criteria for schizophrenia, schizoaffective disorder, 
or delusional disorder, or met entry criteria for an early intervention for psychosis 
service (operationally defined with the Positive and Negative Syndrome Scale 
[PANSS]) as the majority of individuals experiencing their first episode of psychosis 
will receive their services from specialist teams, as recommended by NICE 
guidelines. All participants were aged at least 16 and were in contact with mental 
health services, under the care of a consultant psychiatrist. Participants scored at 
least 4 on PANSS delusions or hallucinations, or at least 5 on suspiciousness, 
persecution or grandiosity and participants had to have the capacity to consent and 
also had to be help-seeking. Individuals were identified via care coordinators, 
consultant psychiatrists and other mental health staff within participating mental 
health trusts. Exclusion criteria were receipt of antipsychotic medication or structured 
CBT with a qualified therapist within the last 3 months; moderate to severe learning 
disability; organic impairment; a score of 5+ on PANSS conceptual disorganisation; 
primary diagnosis of alcohol/substance dependence; immediate risk to self or others 
and non-English speaking.  
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The PANSS was administered by a research assistant in the participant’s home or a 
suitable clinical service, and eligibility was confirmed by a qualified clinician. 
Participants provided written informed consent. Our protocol was approved by 
National Research Ethics Service of the UK’s National Health Service (reference = 
14/NW/0041).  
Randomisation and masking  
Participants were randomly assigned to the three treatment arms (1:1:1) using a 
secure web based randomisation system (Sealed Envelope) with randomised 
permuted blocks of 4 and 6, stratified by gender and first episode status. 
Randomisation at the individual level was independent and concealed with all 
assessors masked to group allocation. Allocation was made known to the trial 
manager, trial administrator and therapists. Participants and their care team were 
informed of the allocation by letter.  Nine partial blind breaks (where only one 
treatment was revealed), representing 12% of participants, and five full blind breaks 
(where actual randomisation arm was revealed), representing 7% of participants, 
were reported by research assistants. Four of the full blind breaks were in the AP 
arm, 1 was in the combined arm and none were in the CBT arm. Only 3 (1.17%) out 
of 256 follow-up assessments were conducted by an unmasked assessor (where the 
blind was broken during the assessment) and all of these assessments were then 
scored by a masked rater and consensus was reached on ratings. This procedure 
ensured that none of the 256 assessments were scored without rater-masking.  
Interventions 
CBT: Participants allocated to CBT were offered up to 25 sessions of therapy based 
on a specific cognitive model (18) over the 6 month treatment window. Therapy was 
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individualised and problem focussed, and the range of permissible interventions are 
described in the manualised treatment protocol (19). Therapy sessions were usually 
offered on a weekly basis and were delivered by appropriately qualified 
psychological therapists. Fidelity to protocol was ensured by weekly supervision and 
regular rating of recorded sessions using the Cognitive Therapy Scale-Revised 
(CTSR) (20).  
Antipsychotic medication: Participants allocated to antipsychotics were prescribed 
this medication by their responsible psychiatrist and their treatment was initiated as 
soon as possible post randomisation. Antipsychotic prescribing mirrored that which 
would be seen in normal clinical practice which meant that there were no restrictions 
on the antipsychotics that could be selected or their doses, and clinicians were able 
to switch antipsychotics and adjust dose as clinically indicated. Clinicians were 
encouraged to continue antipsychotic treatment for a minimum of 12 weeks, and 
preferably for at least 26 weeks. 
Combined treatment: Participants allocated to the combined treatment were offered 
both CBT and antipsychotic medication as described above.  
Clinicians were free to prescribe medication other than antipsychotics including 
antidepressants, anxiolytics and hypnotics for all participants regardless of treatment 
allocation.  
All participants were offered monitoring assessments at 6 weeks, 12 weeks, 24 
weeks and 52 weeks. In order to allay any concerns around safety of withholding 
antipsychotic medication for CBT monotherapy participants, trial procedures included 
monitoring for deterioration with the option to move to the combined treatment arm 
for anyone who was randomised to CBT or AP’s alone, and who experienced a 
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decline in mental state during the trial.  This procedure was detailed in the standard 
operating procedures for the study and was presented to the Research Ethics 
Committee, as well as clinicians who referred to the study.  Participants experiencing 
evidenced deterioration remained in the RCT and the assessment schedule was 
maintained. Participants were given the option to move into the combined treatment 
arm if deterioration in mental state led to involuntary hospitalisation or if there was a 
>25% deterioration in PANSS scores at the 6-week assessment or a >12.5% 
deterioration in PANSS scores at the 12-week assessment.  
Outcomes 
The primary outcome was feasibility operationalised in terms of referral rates, 
recruitment, retention/attrition, acceptability of treatment, attendance at sessions, 
adherence to homework, compliance with medication. The primary effectiveness 
outcome measure was total score on the Positive and Negative Syndrome Scale 
(PANSS) (21) assessed at baseline, 6 weeks, 12 weeks, 24 weeks and 52 weeks. 
The PANSS is a thirty item, semi-structured interview assessing dimensions of 
psychosis symptoms rated on a seven-point scale between 1 (absent) and 7 
(severe). Reliability and validity of the PANSS has been demonstrated in numerous 
studies (22). Measures were administered by research assistants trained in the use 
of all the instruments to achieve a good level of inter-rater reliability (ICC = 0.902). 
Secondary clinical outcomes included depression and anxiety assessed using the 
Hospital Anxiety and Depression Scale HADS:(23)), as well as quality of life 
(WHOQOL (24)) and social functioning assessed using the Personal and Social 
Performance scale (PSP: (25)). We also included a user-defined measure of 
recovery (QPR: (26)) and the clinical impressions of symptom severity and 
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improvement (CGI) scale (27). Service use, diagnosis and antipsychotic prescribing 
were recorded via review of case notes. Non-neurological side effects were 
systemically assessed using the antipsychotic non-neurological side effects scale 
(ANNSERS: (28)). Additional assessments of physical health included weight, blood 
pressure and blood tests for HbA1C, fasting glucose, fasting lipids (total cholesterol, 
LDL, HDL, triglycerides and prolactin levels). At 6 months self-report data on 
antipsychotic adherence in the last month was obtained using a visual analogue 
scale. At the 52 week follow-up, we also surveyed participant’s opinions on their 
preferences and views of measures used in the study to inform choice of measures 
for a definitive trial.  
We report on all outcomes that were specified in our prospectively registered and 
recently published protocol (17) and statistical analysis plan, which was agreed with 
the data monitoring and ethics committee, and a-priori published on the trial registry 
entry.  
Changes to trial protocol following commencement: After the original ethical approval 
for the trial in February 2014, a substantial amendment was made (approved June 
2014): the lower age limit was changed from 18 to 16; ‘inpatient status’ was removed 
as an exclusion criteria and replaced by ‘immediate risk to self or others’; and the 
randomisation time-frame was amended to 5 working days from 2 working days. 
Other minor amendments were made including the addition of service user and 
clinician surveys to gather further information on feasibility of recruitment. We had 
originally proposed that the recruitment window would be variable, with participants 
recruited in the first 22 months receiving the full 6–month follow up, whereas 
participants recruited thereafter would be offered assessments up to the end of 
treatment; however, we agreed a no-cost extension with the funder and were able to 
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complete 12-month follow-up of all participants. We had also originally proposed that 
economic analyses would explore the costs of health and social care and quality 
adjusted life years (QALYs) from a broadly societal perspective; however, the EQ5D 
was omitted from our assessment battery in error, meaning this was not possible.   
Statistical analysis  
The primary outcome for the trial is feasibility, including the number of participants 
referred and the number of consenting individuals and recruited individuals to each 
arm, as well as retention and the proportion of participants receiving the allocated 
intervention versus those who did not. Analyses were undertaken in Stata version 14 
(29) after completion of all endpoint assessments; primary analysis was by intention-
to-treat (ITT). Outcomes were analysed using Stata’s xtreg command to fit random 
intercept models with summed scores as dependent variables, allowing for attrition 
and the variable follow-up times introduced by the design of the trial. Covariates 
included gender, age, time and the baseline value of the relevant outcome measure 
(first episode status, as a stratification factor, should have been included, but with 
only 2 of 75 participants not being first episode, age was a more appropriate 
covariate). The use of these models allowed for the analysis of all available data, on 
the assumption that data were Missing at Random (MAR) (30), conditional upon 
covariates. We report estimated treatment effects, with their standard errors, 
significance levels and confidence intervals. All treatment effects reported here are 
estimates of the effects common to all follow-up times (essentially, repeated 
measures ANCOVAs).  Since safety and unwanted effects should be analysed on 
the basis of the most accurate information, these results are reported using an as 
treated approach rather than ITT. As treated was defined using our pre-defined 
minimum dose criteria for both antipsychotics (at least 6 weeks at a therapeutic 
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dose) and CBT (at least 6 sessions); on this basis, participants were classified as 
having received antipsychotics, CBT, combined or neither. 
Role of the funding source 
The sponsor of the study had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report or in the decision to submit for publication.  
Data sharing 
Anonymised data will be made available upon reasonable request, which must 
include a protocol and statistical analysis plan and not be in conflict with our pre-
specified publication plan, consistent with our data sharing policy (available on 
request from the Chief Investigator). Requests for data sharing will be considered by 
the Chief Investigator and the independent Trial Steering and Data Monitoring 
Committee. 
Results  
Figure 1 shows the CONSORT diagram for the trial and Table 1 shows the baseline 
data for each group. The planned recruitment target of 75 was achieved, indicating it 
is feasible to recruit individuals to such a trial. The referral to recruitment rate was 
2:1, with only 22 out 138 referrals (16%) declining to participate suggesting 
willingness to be randomised and consider each of the treatment options. It is clear 
that recruiting eligible participants was easier in EITs, with those experiencing FEP 
(73/75 of participants), compared to recruiting multi-episode patients from CMHTs. 
We randomised participants from 10 of 22 participating clinical teams (Web 
Appendix Table 1). 75 individuals were randomised and allocated to Cognitive 
Behaviour Therapy (n= 26), antipsychotics (n=24) or a combination of both (n=25). 
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Retention to the trial was reasonable (see figure 1), with only four withdrawals and 
relatively low rates of attrition (e.g. 63 of the 75 12-month assessments (84%) were 
completed). Rates of attrition were very similar across each arm (see Figure 1).  
Participants who were randomised to CBT (in either the CBT or combined arm) 
received a mean of 14.39 sessions (SD 9.12, range 0-26) within the 6 month 
treatment window, with each session lasting around an hour (additional booster 
sessions were also offered as appropriate). The majority of participants (n=40 out of 
51, 78%) attended 6 or more sessions, with only one participant (2%) attending no 
sessions. Homework compliance was good for both participants (404 of 557 
participant between session tasks were completed (73%)) and therapists (396 of 445 
therapist between session tasks were competed (89%)). 
Of the 49 participants randomised to antipsychotic monotherapy or combined 
treatment, 11 (22%) were not prescribed a regular antipsychotic; reasons varied but 
included some participants declining to take an antipsychotic despite consenting to 
enter the trial. The modal dose for each participant was the most frequent daily dose 
of the primary antipsychotic i.e. the antipsychotic prescribed for the longest period 
during the study. The three most common primary antipsychotics prescribed were 
aripiprazole (n=14), olanzapine (n=10) and quetiapine (n=10), as chosen by the 
treating psychiatrist in the participants clinical care team (Table 2).The mean modal 
dose for each antipsychotic was defined as the mean of the modal doses for patients 
prescribed that drug (Table 2). Duration of antipsychotic treatment for each 
participant was based on all regular antipsychotics prescribed and was not restricted 
to the primary antipsychotic; 12 of the 38 participants (32%) treated with an 
antipsychotic, switched antipsychotics at least once during the study. Nearly all 
participants who commenced antipsychotic treatment  were prescribed their primary 
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antipsychotic for 6 weeks or more (34/37, 92%; duration was not captured for 1 
participant), and the median duration of total antipsychotic treatment was 44.5 weeks 
(SD 16.1, range 2-52).. 28/36 (78%) of participants with accurate duration data were 
continuing antipsychotic medication at the end of the study. 
Self-reported data on medication adherence was available at 6 months for 42 of the 
49 participants (86%) randomised to antipsychotic monotherapy or combined 
treatment. 29 of the 42 participants (69%) reported being prescribed an  
antipsychotic at that time point. Among these 29 participants, mean adherence 
(rated on a scale of 0% to 100%, with 100% indicating they had taken every dose 
over the last month) was 77% (range 0 -100%, SD 29.19).  
The proportion of patients receiving allocated interventions was similar across 
groups (Table 3); 15/26 in the CBT alone arm (58%) received the exact allocated 
intervention (i.e. CBT without antipsychotics) as compared to 15/24 (62%) in the anti-
psychotic group and 14/25 in the combined group (56%).  Only 9 participants (12%) 
received an intervention that they were not allocated to.  
 
Psychiatric symptoms, measured by PANSS Total, were significantly reduced over 
time across all conditions (see Web Appendix Figure 1). Tables 4 and 5 show the 
ITT results of the primary effectiveness outcome (PANSS) and the secondary 
outcome measures at each assessment point, along with treatment effect estimates 
and confidence intervals as well as p values for pairwise comparisons. Web 
Appendix Table 2 shows the PANSS analyses without covarying for age.  
We report numbers of participants in each group (completer-only data i.e. observed 
cases) achieving a 25% and 50%  improvement (ITT) and deterioration (as treated) 
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on adjusted PANSS total scores (31) at both 6 months and 12 months (Table 6), as 
has been recommended for trials using the PANSS (32).  
 
Table 7 shows the results, on an as treated basis, of the measures of adverse 
effects at each assessment point, along with treatment effect estimates and 
confidence intervals as well as p values for pairwise comparisons.  We also 
examined compulsory and voluntary hospital admissions during the trial; the data 
regarding type, number and length of stay for psychiatric hospital admissions is 
provided in table 8. Using an as treated analysis (rather than ITT) there were no 
admissions among those treated with antipsychotic monotherapy or among those 
who received no intervention.  2 participants treated with CBT were admitted and 4 
who received combined treated were admitted.  
 
We also recorded another 10 potential serious adverse events relating to 9 
participants (2 adverse events were related to 1 participant). The 9 participants were 
randomised to the following treatment arms: APs n=1, CBT n=4, combined n=4. In 
terms of the interventions these 9 participants actually received, one received neither 
intervention, 2 received CBT and 6 received the combined treatment. The additional 
10 potential SAEs included: two admissions related to physical health (one 
participant in the combined as treated group experienced seizures which led to a 
head injury and admission to medical ward, one participant who received neither 
intervention from the trial was admitted to a medical ward due to pneumonia); and 
one admission following an overdose (participant was in the combined as treated 
group). There was also one event involving aggression to others whilst in hospital 
(participant was in the combined as treated group), four attempted overdoses of five 
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or less paracetamol or eight sleeping tablets (these four events related to three 
participants, one in the combined as treated group and two in the CBT as treated 
group), one report of self-harm in the form of superficial cutting (combined as treated 
group) and one A&E attendance following reports of suicidal thoughts and self-harm 
by punching objects (combined as treated group).  
These SAEs were reviewed by the chair of the independent trial steering committee, 
resulting in six reports being sent to the Research Ethics Committee. These related 
to 5 different participants: two in the CBT as treated group (events were section 3 
hospitalisation and overdose of 3 paracetamol tablets); and 4 in the combined as 
treated group (events were superficial cutting; physical health hospital admission 
following seizures and head injury; informal admission due to risk to self and one 
hospital admission following an overdose). Only one SAE was considered related to 
the trial (the overdose of 3 paracetamol tablets in the CBT participant). 
Regarding participants who met our deterioration criteria at 6 or 12 weeks, which 
triggered an offer to move into the combined arm, only 3 participants met this 
threshold (2 from antipsychotics only, one from CBT only). 
 
Discussion 
The COMPARE trial has demonstrated that it is possible to conduct a study 
comparing antipsychotics with CBT and a combined treatment in people with 
psychosis. This pragmatic pilot and feasibility trial had low attrition (<20% at each 
time point), comparable attrition across each trial arm, high retention of participants, 
low rates of unblinding, successful concealed and independent randomisation and 
only a small proportion of participants who received an intervention that they were 
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not allocated to receive. All 3 treatments were broadly safe and acceptable. The 
mean baseline PANSS total scores for our total sample was 70.4 which is similar to 
the baseline PANSS score of 73.8 seen in the CAFÉ study (33), but lower than the 
88.5 seen in EUFEST (34) (both are large, 1-year RCTs of antipsychotics in early 
psychosis). The average changes in PANSS total we observed from baseline to 52 
weeks (antipsychotics: 13.3; CBT: 12.3; combined: 13.4) fall within the range seen 
with the 3 antipsychotics in CAFÉ (olanzapine = 18.4, quetiapine = 15.6 and 
risperidone = 8.4), but are lower than the changes seen in EUFEST (approximately 
35 points with all five antipsychotics assessed). The average PANSS reductions we 
observed are less than the 15 points estimated to be equivalent to a rating of 
‘minimal improvement’ on the Clinical Global Impressions (CGI) scale (35), although 
it is suggested the latter value is lower for patients with less severe symptoms at 
baseline (35). These reductions were larger than estimates for  minimal clinically 
important difference (MCID) in PANSS Total associated with obtaining employment 
as an objective measure of functioning (8.3 points) (36) and similar to the MCID 
associated with patient-rated improvement (11.2 points) (37). We observed 
improvement across measures of symptoms and personal and social recovery, 
functioning and quality of life, regardless of intervention condition.  
There is a signal that the combined group may be superior to both monotherapies, 
with some significant differences in comparison to CBT alone (including PANSS 
total, p=0.019) and trends in comparison to antipsychotics alone (including PANSS 
total, p=0.06). It would appear that these differences are most pronounced at 24 
weeks, but the effects of treatments seemed to converge at 52 weeks. However, 
since this is a pilot and feasibility study, it was not powered to reliably detect 
differences between groups and any such differences should be treated with 
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considerable caution. There was little to signal that there were any significant 
differences in efficacy between the two monotherapies, which is interesting given 
CBT finished after 24 weeks whereas antipsychotic treatment could last 52 weeks 
(the median duration among those who received APs was 44.5 weeks). It is also 
interesting that there appears to be no difference between the 3 groups after 6 
weeks (see Web Appendix Figure 1), given this is a common length for drug trials. 
The number of participants with PANSS rated deterioration was low across all 
groups at each time point, with no indication that CBT was worse than antipsychotics 
or combined. . Notably, there were only 3 early deteriorations (at 6 or 12 weeks), 
with 2 from the antipsychotics only arm and 1 from the CBT only arm. 
Data regarding side effects provide a signal that CBT monotherapy may be superior 
to antipsychotic monotherapy and the combined intervention, since there were 
significant differences on both ANNSERS total score and number of side effects 
reported. However, close inspection shows this is more accounted for by a reduction 
in these in CBT monotherapy, rather than an increase in the antipsychotic arms; this 
could be related to many ANSSERS items being non-specific (for example, sleep 
problems, memory and attention, loss of libido, loss of energy and autonomic 
symptoms). Such symptoms could represent symptoms of a psychotic disorder, a 
comorbid illness or be ‘true’ antipsychotic side effects. There was also a signal that 
serious adverse events (SAEs), including hospital admissions, may be more 
common in the arms involving CBT, since there were no such admissions for 
antipsychotic monotherapy (although CBT monotherapy was associated with fewer 
admissions than the combined arm). Similarly, there were no SAEs reported to the 
ethics committee for antipsychotic monotherapy, with two for CBT monotherapy and 
four for combined intervention, although only one SAE was considered related to the 
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trial. However, this should be interpreted cautiously given that this pilot trial was 
under-powered. It is also worth considering that there is increased surveillance and 
opportunity for SAEs to be observed in the CBT arms, since CBT had weekly contact 
with trial staff tasked with reporting adverse effects (the trial therapists), whereas 
antipsychotic monotherapy participants had much less frequent contact with trial staff 
(the trial RAs), resulting in a maximum of 35 opportunities for such events to be 
detected for CBT arms versus 5 opportunities for antipsychotic monotherapy.     
The number of sessions attended and compliance with homework tasks suggests 
that CBT was delivered successfully to the majority of participants. Selection of 
antipsychotic medication was on an individual patient basis, consistent with NICE 
guidance. The four antipsychotics used most frequently (aripiprazole, olanzapine, 
quetiapine, risperidone) correspond to the four antipsychotics most commonly 
initiated in routine clinical practice in first episode services as reported in a recent 
cohort study (38) of 510 FEP participants across seven sites in the UK. Antipsychotic 
dose and duration of treatment were not limited by the protocol and were entirely at 
the discretion of the treating clinician and patient wishes. One patient’s primary 
antipsychotic was promazine, a drug approved to treat agitation and not psychosis, 
and the dose was very low and insufficient to be regarded as an effective 
antipsychotic dose (table 2). The mean modal doses of the remaining primary 
antipsychotics were at the lower end of the dose ranges recommended to treat 
psychosis, but this is consistent with participants being recruited almost exclusively 
from early intervention services.  People with first-episode psychosis respond to 
lower doses of antipsychotic medication than those required to treat multi-episode 
schizophrenia (33) and are more sensitive to side effects.  As such, expert 
pharmacological guidelines recommend commencing antipsychotic treatment with 
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low doses in first episode of psychosis and that an adequate trial of an antipsychotic 
is up to 4 weeks at optimum dosage (39). The International Consensus Study of 
Antipsychotic Dosing recommended 30% lower doses were used in first episode 
patients compared to chronic patients (40).  Nevertheless, the doses of some of the 
antipsychotics, especially quetiapine, were lower than the comparable doses used in 
the CAFÉ and EUFEST trials in first episode psychosis. In most cases, where 
duration of antipsychotic treatment was known (34/37, 92%), the primary 
antipsychotic was continued for 6 weeks or longer suggesting that treatment duration 
was sufficient to determine effectiveness. 12 of the 38 (32%) participants who started 
antipsychotic treatment switched  antipsychotic at least once implying perseverance 
to identify an effective medication. In summary, the use of antipsychotic medication 
was pragmatic and seems broadly consistent with clinical practice in EI services and 
treatment guidelines; therefore, results should generalise to this context. However,  a 
question remains as to whether higher doses would have improved outcomes 
(although they would increase side effects which may also lead to discontinuation).  
There are several limitations for this trial. The pilot and feasibility trial design and 
small sample size means that we cannot emphasise the statistical tests and 
significance values and need to exercise caution in interpreting these. With regard to 
integrity of treatment allocation, although only 12% received an intervention they 
were not allocated to receive, a reasonable proportion did not take up the offer of 
allocated interventions (31% of those allocated to an antipsychotic did not take one 
for at least 6 weeks and 22% of those allocated to CBT did not attend at least 6 
sessions). However, this reflects the real world in which many people do not comply 
with medication regimes and some do not engage with talking therapies, and such 
rates of non-adherence are commonly observed in drug trials and psychological 
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therapy trials. Indeed, a recent cohort study of 510 FEP participants found that 73%  
discontinued their first prescribed antipsychotic over 52 weeks (38).  
The dose and duration of the antipsychotic treatment has already been referred to. It 
could be argued that operationalising antipsychotic treatment in terms of target 
doses, minimal duration of trials and encouraging switching if treatment was 
unsatisfactory may have enhanced the effectiveness of drug treatment.  However 
higher doses may have led to more side effects and greater dropout rates. 
COMPARE relied on medication being prescribed and dispensed in accordance with 
normal clinical practice in the participating teams. In contrast, drug trials often deliver 
medication to patients and incorporate regular pill counts, both of which may 
enhance adherence. The lack of an effect on weight gain in the antipsychotic 
monotherapy group may cast doubt on adherence; however, the total number of side 
effects and total side effects score (ANNSERS) were significantly higher for the 
antipsychotic monotherapy and the combination group versus the CBT group 
(analysed on an as treated basis), although this was accounted for by a reduction in 
the CBT group rather than increases in the antipsychotic arms. We did not have a 
standardised operating procedure for measuring weight that emphasised 
consistency of flooring and many assessments were conducted in participants 
homes; therefore, it is also possible that the weight data contained errors. Another 
limitation is that we did not systematically record use of other medications such as 
antidepressants or anxiolytics or measure substance and alcohol use. 
Our response rates on the PANSS (table 6) and the degree of improvement on the 
CGI were lower than those observed in 52-week RCTs of antipsychotic medication in 
FEP (33, 34). However, data analytic strategies and high attrition in these studies 
may have increased risk of bias, which could inflate effects. For example, EUFEST 
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used data obtained before treatment discontinuation for analysis of PANSS 
outcomes, which is likely to introduce bias given the high rates of discontinuation 
(ranging from 33-72% depending on the specific drug). CAFÉ had very high attrition 
at 52 weeks (ranging from 67% to 73% depending on drug), which is also likely to 
introduce bias given the majority of data is missing at this time point. Response is 
also dependent on patient and illness characteristics and these vary between 
studies; for example, COMPARE mostly involved participants who met PANSS-
defined criteria for acceptance into EITs, whereas EUFEST and CAFÉ only included 
participants with schizophrenia spectrum diagnoses.   
Our sample was diagnostically heterogeneous, since we recruited 73/75 of our 
participants from EITs, which operationally define FEP using the PANSS. Most 
participants did not have diagnoses in the medical records at baseline, with the most 
common entry being First Episode Psychosis and the most common formal ICD-10 
diagnosis being F29 unspecified non-organic psychosis. Therefore, it is likely that 
our findings are only generalisable to early intervention services, at least in the UK. 
The results should not be generalised to those with chronic schizophrenia spectrum 
diagnoses including those seen within adult community mental health teams 
(CMHTs), and it is possible that a more homogenous schizophrenia spectrum 
sample may have responded differently to the treatments.  
The design of our study (3 active treatment arms), alongside the majority of 
participants receiving care from early intervention services, means we cannot rule 
out the possibility that the benefits observed are attributable to more generic factors 
such as good care-coordination, engagement, assertive outreach and crisis 
management, rather than the specific active treatments. The failure to include the 
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EQ5D meant we were unable to examine quality adjusted life years and any signals 
regarding cost-effectiveness. 
Given that the safety and feasibility of such a trial has been demonstrated, a large, 
efficacy and effectiveness  randomised controlled trial is now required to answer the 
questions regarding the relative clinical and cost-effectiveness of CBT and 
antipsychotics in a head-to-head comparison. This trial demonstrated that the 
randomised participants were almost exclusively experiencing a first episode of 
psychosis, so a definitive trial should target this population specifically and recruit via 
early intervention services, which seemed to support treatment choice and view the 
question of which treatments are required with greater equipoise than the more 
generic community mental health teams. It does not appear feasible to conduct such 
a trial in people with multiple episode psychotic disorders in generic community 
mental health teams (mostly because potential participants are already prescribed 
antipsychotics). Given the possibility of non-adherence and variation in the quality of 
antipsychotic treatment between clinical teams, for example in terms of dose, 
duration of treatment before switching, and information given, it may be worth an 
efficacy and effectiveness  trial employing research psychiatrists to help standardise 
the quality of  antipsychotic treatment; however, this may jeopardise support from 
clinical teams and local Consultant Psychiatrists. It may also be worth considering 
the introduction of: a diagnostic interview to allow accurate reporting of diagnoses; a 
measure of substance misuse to allow characterisation of the population; and a 
placebo condition to facilitate meaningful comparisons of response rates (although 
this could raise ethical issues). On the basis of our data, it would seem reasonable to 
suggest that an efficacy and effectiveness  trial should evaluate the following 
hypotheses: i) CBT will be equivalent to antipsychotics on efficacy; ii) CBT will be 
29 
 
superior to antipsychotics on side effects; iii) the combined intervention will be 
superior in efficacy to both monotherapies. Further consideration, including 
consultation of stakeholders such as service users and clinicians, is required to 
inform the selection of the most appropriate outcome measure an efficacy and 
effectiveness  trial (for example, symptom change, quality of life or subjective 
recovery). 
The main implication of this trial is that we need an adequately powered  efficacy and 
effectiveness  trial to provide evidence regarding relative effectiveness of 
antipsychotic medication and CBT. At present, in the absence of definitive evidence, 
and the fact that evidence supporting antipsychotic monotherapy is notably stronger 
than that supporting CBT monotherapy, it seems reasonable to support people with 
psychosis (who do not present immediate risk to self or others) to make informed 
choices as outlined the NICE guidelines, which recommend advising people who 
want to try psychological interventions alone that these are more effective when 
delivered in conjunction with antipsychotic medication, but allowing them to to try 
family intervention and CBT without antipsychotics while agreeing a time to review 
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Screened for eligibility (n=138) 
Total excluded (n=63) 
 
Not meeting inclusion criteria (n=36) 








Complete N= 20 (76.92%) 
Missed  N = 6 (23.08%) 
Withdrawn N= 0  
 
Allocated to CBT (n=26) 
 
Allocated to Antipsychotics (n=24) Allocated to Combined (n=25) 
6-week assessment 
Complete N= 22 (91.67%) 
Missed N=1 (4.17%) 




Complete  N=20 (80.0%) 
Missed N=4 (16.0%) 




Complete  N=23 (88.46%) 




Complete N=22 (91.67%) 
Missed N=1 (4.17%) 




Complete  N=20 (80.0%) 
Missed N=4 (16.0%) 




Complete N=22 (84.62%) 
Missed  N=3 (11.54%) 
Withdrawn N=1 (3.85%) 
 
24 week assessment 
Complete N=22 (91.67%) 
Missed N=1 (4.17%) 




Complete  N=22 (88.0%) 
Missed N=1 (4.0%) 




Complete N=21 (80.77%) 
Missed N=4 (15.38%) 
Withdrawn N=1 (3.85%) 
 
52-week assessment 
Complete  N=22 (91.67%) 
Missed N=1 (4.17%) 




Complete N=20 (80.0%) 
Missed N=3 (12.0%) 









CBT (N=26) Combination 
(N=25) 
Age (years) 23.21 (4.97) 23.19 (6.32) 24.44 (6.86) 
Male 13 (54%) 16 (62%) 14 (56%) 
FEP: Multiple episode 24:0 24:2 25:0 
DUP (weeks) 37.33 (44.41) 44.48 (52.30) 39.43 (35.76) 
PANSS total 70.17 (10.12) 70.50 (8.12) 70.76 (8.45) 
PANSS Positive 23.04 (4.60) 23.15 (4.63) 21.92 (3.63) 
PANSS Negative  16.17 (5.72) 15.5 (4.10) 15.24 (5.17) 
PANSS disorganised 16.25 (2.60) 17.15 (3.65) 17.8 (4.27) 
PANSS Excitement 18.25 (4.35) 17.85 (3.86) 17.4 (4.14) 
PANSS Emotional Distress 25.46 (5.00) 25.31 (3.83) 26.28 (3.47) 
QPR total 38.71 (9.23) 40.13 (9.33) (n=25) 41.8 (11.79) 
HADS Total 41.05 (5.49) (n=23) 37.54 (5.42) (n=24) 36.36 (6.76) 
HADS Anxiety 21.96 (2.62) (n=23) 20.5 (3.32) (n=24) 19.36 (3.89) 
HADS Depression 19.05 (4.87) (n=23) 17.38 (3.32) (n=24) 17.28 (5.55) 
WHO Qol total 67.03 (14.99) 68.66 (13.41) (n=25) 70.18 (15.41) (n=24) 
PSP 52.67 (13.83) 57.38 (12.04) 58.16 (11.1) 
CGI participant version 4.91 (0.97) (n=22) 4.42 (0.99) 4.38 (1.54) 
CGI clinician version 4.13 (0.74) 4.08 (0.63) 4.04 (0.68) 
ANNSERS total number of 
side effects 9.96 (4.72), 24 8.88 (3.77), 26 9.16 (4.69), 25 
ANNSERS 
Total score 13.92 (7.05), 24 12.12 (6.55), 26 12.28 (6.61), 25 
Cholesterol (mmol/l) 4.54 (0.91), 20 4.08 (0.82), 15 4.45 (0.93), 16 
HDL- Cholesterol (mmol/l) 1.34 (0.35), 20 1.13 (0.3), 15 1.38 (0.4), 15 
Total/HDL ratio 3.57 (0.94), 20 3.5 (0.86), 15 3.35 (0.93), 15 
LDL Cholesterol (mmol/l) 2.58 (0.78), 15 2.33 (0.67), 12 2.46 (0.68), 14 
Triglycerides (mmol/l) 1.15 (0.39), 16 1.27 (0.64), 12 1.12 (0.45), 14 
Prolactin (mU/l) 183.06 (89.71), 17 187.07 (63.33), 15 198.5 (81.78), 14 
Glucose (mmol/l) 6.27 (6.96), 18 5.32 (2.41), 15 4.14 (0.55), 15 
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Table 2: Antipsychotic details for participants in the antipsychotic monotherapy arm 






dose (mg per 
day for oral 
drugs) 
Max dose 
used (mg per 
day for oral 
drugs) 
Aripiprazole 14 10.6 20 
Olanzapine 10 8  10 
Quetiapine 10 270  700 
Risperidone 2 2.5  3 












Table 2:  
* Primary antipsychotic = antipsychotic prescribed to each participant for longest duration during 




Table 3: Participants randomised vs as treated status 
 










 Antipsychotics  CBT  
 
Combination  Total 
Antipsychotics  15 2 4 21 
CBT  0 15 5 20 
Combination  1 6 14 21 
Neither 8 3 2 13 










(N = 24) 
CBT 
(N = 26) 
Combination 
(N = 25)  
Mean difference (SE); (95%CI); P-value 
CBT vs. AP CBT vs. combined AP vs. combined 









6 64.05 (11.39), 22 64.85 (7.85), 20 64.7 (9.74), 20 
12 60.81 (16.52), 21 63.74 (7.73), 23 58.4 (14.51), 20 
24 61.09 (14.44), 22 60.5 (8.74), 22 53.77 (12.54), 22 
52 56.77 (14.1), 22 58.14 (11.68), 21 57.4 (13.58), 20 









6 19.36 (5.44), 22 21 (4.38), 20 20.1 (4.41), 20 
12 19.19 (7.72), 21 21 (4.72), 23 17.4 (5.65), 20 
24 17.81 (6.85), 21 18.18 (4.81), 22 15.23 (5.31), 22 
52 18.18 (6.52), 22 17.9 (5.92), 21 16.8 (6.05), 20 









6 14.64 (5.06), 22 15.05 (3.52), 20 13.9 (4.85), 20 
12 14 (4.32), 21 14.83 (3.1), 23 13 (5.23), 20 
24 14.14 (5.47), 22 14.91 (4.72), 22 12.41 (4.6), 22 
52 12.73 (4.58), 22 14.62 (4.52), 21 12.8 (3.68), 20 
PANSS 
Disorganised 









6 15.77 (3.18), 22 16.8 (2.91), 20 17.5 (4.01), 20 
12 15.19 (4.96), 21 16.39 (3.37), 23 16.25 (4.1), 20 
24 15.1 (3.86), 21 15.5 (3.53), 22 14.5 (3.78), 22 
52 14.82 (3.67), 22 15.67 (3.73), 21 15.8 (4.25), 20 
PANSS 
Excitement 









6 15.95 (4.09), 22 15.9 (3.93), 20 15.75 (4.05), 20 
12 15.52 (4.77), 21 15.52 (3.16), 23 14.35 (4.97), 20 
24 14.77 (3.37), 22 14.45 (3.4), 22 12.86 (4.36), 22 













6 22.55 (5.21), 22 21.5 (4.27), 20 23.1 (3.93), 20 
12 21.38 (6.91), 21 22.48 (4.31), 23 19.6 (5.74), 20 
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24 21.55 (5.75), 22 20.95 (3.7), 22 17.5 (5.49), 22 









(N = 24) 
CBT 
(N = 26) 
Combination 
(N = 25)  
Mean difference (SE); (95%CI); P-value 
CBT vs. AP CBT vs. combined AP vs. combined 
QPR 0 38.71 (9.23), 24 40.13 (9.33), 25 41.8 (11.79), 25 -0.93 (2.97); 
(-6.76, 4.90); 
0.754 






24 44.86 (14.99), 22 47.81 (8.86), 21 52 (14.05), 18 
52 48.55 (14.73), 22 51.62 (9.25), 21 49.88 (11.04), 17 









24 35.55 (7.69), 22 35.36 (12.61), 22 30.37 (9.28), 19 
52 34.27 (9.08), 22 32.14 (6.96), 21 30.35 (6.98), 17 









24 19.36 (4.51), 22 19.18 (10.8), 22 15.65 (5.98), 20 
52 18.73 (5.03), 22 17.29 (4.64), 21 15.67 (4.89), 18 









24 16.27 (5.84), 22 15.18 (3.81), 22 13.42 (5.83), 19 
52 14.91 (5.52), 22 14.05 (4.2), 21 14.94 (5.36), 17 









6 72.5 (19.84), 22 76.78 (14.79), 18 77.82 (14.06), 17 
12 77.29 (21.31), 21 79.29 (16.59), 21 85.83 (17.59), 18 
24 79.15 (20.95), 20 79.1 (14.03), 21 89.06 (18.87), 18 
52 81.36 (20.02), 22 83.81 (15.23), 21 82.93 (19.17), 15 









24 63.95 (18.53), 22 60.05 (10.51), 22 62.48 (17.47), 21 
52 60.45 (17.61), 22 60.95 (12.93), 21 61 (16.47), 20 
CGI Scale 
(clinician) 









24 3.32 (1.17), 22 3.45 (0.91), 22 2.86 (1.06), 21 
52 3.23 (1.11), 22 3.38 (1.07), 21 3 (1.08), 20 
CGI Scale 
(Patients) 









24 4.33 (1.56), 21 3.71 (1.23), 21 3.2 (1.54), 20 
52 3.91 (1.48), 22 3.5 (1.5), 20 3.94 (1.59), 18 
CGI clinician - 
improvement 





(-1.19, 0.03); 24 2.95 (1.21), 22 2.78 (1.23), 22 2.14 (0.91), 21 
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Table 6: Participants achieving improvement/deterioration on PANSS total score at 24 and 52 weeks 
ITT analysis Deterioration (n) Improvement (n) 
>25% >50% >25% >50% 
24 
weeks 
CBT 0 2 8 2 
Antipsychotics 0 1 5 3 
Combination 0 0 11 7 
52 
weeks  
CBT 0 1 8 4 
Antipsychotics 2 0 8 5 
Combination 0 0 7 6 
As Treated analysis Deterioration (n) Improvement (n) 
>25% >50% >25% >50% 
24 
weeks 
CBT 0 1 8 3 
Antipsychotics 0 1 3 2 
Combination 0 1 9 4 
Neither 0 0 4 3 
52 
weeks  
CBT 0 0 6 6 
Antipsychotics 2 0 6 0 
Combination 0 1 8 4 











(N = 21) 
CBT 
(N = 20) 
Combination 
(N = 21)  
Mean difference (SE); (95%CI); P-value 
CBT vs. AP CBT vs. combined AP vs. combined 
ANNSERS total 
number of side 
effects+ 









24 8.47 (5.62), 17 5.7 (3.23), 20 10.05 (5.35), 19 
52 9.06 (5.5), 16 4.74 (3.35), 19 10.42 (5.9), 19 
ANNSERS 
Total score+ 









24 11.59 (8.4), 17 7.45 (4.99), 20 14.16 (8.42), 19 
52 12.94 (8.77), 16 6.21 (5.07), 19 13.79 (7.63), 19 
HDL- 
Cholesterol(mmol/l) 









12 1.37 (0.38), 14 1.21 (0.29), 9 1.54 (0.49), 15 
52 1.15 (0.36), 8 1.36 (0.31), 6 1.24 (0.21), 7 









12 3.63 (1.25), 14 3.64 (0.44), 10 3.23 (0.65), 14 
52 4.41 (2.11), 8 3.51 (0.53), 7 3.68 (1.05), 6 
LDL Cholesterol 
(mmol/l) 









12 2.59 (0.72), 12 2.79 (0.92), 8 2.63 (0.74), 12 
52 3.02 (0.84), 6 2.83 (0.59), 6 2.63 (0.9), 6 
Triglycerides 
(mmol/l) 









12 1.45 (0.75), 12 1.4 (0.63), 8 1.11 (0.63), 13 
52 1.62 (1.11), 6 0.97 (0.28), 6 2.57 (4.08), 7 














0.281 12 206.92 (83.76), 13 196.22 (83.08), 9 180 (73.9), 10 
52 136.71 (53.84), 7 201.83 (93.32), 6 186.13 (88.69), 8 









12 4.76 (1.1), 11 5.2 (1.72), 7 4.55 (0.55), 14 
52 4.63 (0.65), 8 5.32 (1.81), 6 4.11 (0.76), 7 
Weight (kg) 0 75.91 (20.31), 21 73.62 (15.72), 18 70.93 (12.97), 21 1.80 (1.40); 3.70 (1.41); 1.90 (1.36); 
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0.162 12 72.87 (13.32), 16 73.58 (15.66), 19 73.86 (14.01), 19 
24 78.21 (17.38), 18 72.12 (15.14), 20 75.33 (13.59), 16 
52 74.87 (15.34), 16 75.71 (14.88), 15 75.22 (15.07), 18 
Systolic Blood 
Pressure (mm Hg) 
























116.9 (8.47), 18 
 
 
+ ANNSERS consists of 43 non-neurological side effects each rated as absent (0), mild (1), moderate (2) or severe (3) giving a total score of 129  
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Table 8: Hospital admissions on an as treated basis 
 
 Antipsychotics (N = 
21 ) 




Voluntary admission   
Total number of 
admissions 
0 2 3 0 
Number (%) of 
participants 
admitted 
0 1 (5%) 2 (10%) 0 
Mean (SD) days 
in hospital 
0 35 (21.2) 67 (88.4) 0 
Compulsory admission  
Total number of 
admissions 




0 2 (10%) 1 (5%) 0 
Mean (SD) days 
in hospital 
0 65.5 (54.45) 18 0 
 
 
